Small-molecule anti-HER2 TKIs act on the intracellular domain of the receptor, and mainly include neratinib, lapatinib, pyrotinib, poziotinib and tucatinib which can covalently bind to the intracellular ATP-binding site and inhibit tumor signaling. This evidence concerns the gene ERBB2 and neoplasm.